

LIVER DISORDERS PANEL DG-4.1.0 (171 GENES)

| <i>Gene</i> | <i>Twist X2 covered 10x</i> | <i>Twist X2 covered 20x</i> | <i>srWGS covered 10x</i> | <i>srWGS covered 15x</i> | <i>srWGS covered 20x</i> | <i>Associated Phenotype description and OMIM disease ID</i> |
|-------------|-----------------------------|-----------------------------|--------------------------|--------------------------|--------------------------|---|
| ABCB11 | 100% | 100% | 100% | 100% | 99.6% | Cholestasis, benign recurrent intrahepatic, 2, 605479;Cholestasis, progressive familial intrahepatic 2, 601847 |
| ABCB4 | 100% | 100% | 100% | 100% | 99.7% | Gallbladder disease 1, 600803;Cholestasis, intrahepatic, of pregnancy, 3, 614972;Cholestasis, progressive familial intrahepatic 3, 602347 |
| ABCC2 | 100% | 100% | 100% | 100% | 99.6% | Dubin-Johnson syndrome, 237500 |
| ABCD3 | 100% | 100% | 100% | 100% | 99.8% | ?Bile acid synthesis defect, congenital, 5, 616278 |
| ACOX2 | 100% | 100% | 100% | 100% | 99.3% | Bile acid synthesis defect, congenital, 6, 617308 |

| | | | | | | |
|--------|-------|-------|------|-------|-------|---|
| ACTA2 | 100% | 100% | 100% | 100% | 99.5% | Smooth muscle dysfunction syndrome, 613834;Aortic aneurysm, familial thoracic 6, 611788;Moyamoya disease 5, 614042 |
| ACTG2 | 100% | 100% | 100% | 99.9% | 99% | Megacystis-microcolon-intestinal hypoperistalsis syndrome 5, 619431;Visceral myopathy 1, 155310 |
| ADK | 90.9% | 90.9% | 100% | 100% | 99.8% | Hypermethioninemia due to adenosine kinase deficiency, 614300 |
| AHCY | 100% | 100% | 100% | 100% | 99.3% | Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase, 613752 |
| AKR1D1 | 100% | 100% | 100% | 100% | 99.8% | Bile acid synthesis defect, congenital, 2, 235555 |
| ALDOB | 100% | 100% | 100% | 100% | 99.6% | Fructose intolerance, hereditary, 229600 |
| ALG8 | 77.9% | 77.5% | 100% | 99.9% | 99.5% | Congenital disorder of glycosylation, type 1h, 608104;Polycystic liver disease 3 with or without kidney cysts, 617874 |

| | | | | | | |
|--------|-------|-------|------|-------|-------|--|
| ALG9 | 100% | 100% | 100% | 100% | 99.6% | Gillessen-Kaesbach-Nishimura syndrome, 263210; Congenital disorder of glycosylation, type II, 608776 |
| AMACR | 100% | 100% | 100% | 100% | 99.5% | Alpha-methylacyl-CoA racemase deficiency, 614307; Bile acid synthesis defect, congenital, 4, 214950 |
| ANKS6 | 99.7% | 98.6% | 100% | 100% | 99.3% | Nephronophthisis 16, 615382 |
| AP1S1 | 100% | 100% | 100% | 99.9% | 99.1% | MEDNIK syndrome, 609313 |
| ARCN1 | 100% | 100% | 100% | 100% | 99.7% | Short stature-micrognathia syndrome, 617164 |
| ATP7B | 100% | 100% | 100% | 100% | 99.7% | Wilson disease, 277900 |
| ATP8B1 | 100% | 100% | 100% | 100% | 99.5% | Cholestasis, progressive familial intrahepatic 1, 211600; Cholestasis, intrahepatic, of pregnancy, 1, 147480; Cholestasis, benign recurrent intrahepatic, 243300 |

| | | | | | | |
|---------|-------|-------|------|-------|-------|--|
| B4GALT1 | 100% | 100% | 100% | 99.9% | 98.7% | Combined low LDL and fibrinogen, 620364; Congenital disorder of glycosylation, type II, 607091 |
| BAAT | 100% | 100% | 100% | 100% | 99.5% | Bile acid conjugation defect 1, 619232 |
| BCS1L | 100% | 100% | 100% | 100% | 99.4% | GRACILE syndrome, 603358; Mitochondrial complex III deficiency, nuclear type 1, 124000; Bjornstad syndrome, 262000 |
| BLVRA | 100% | 100% | 100% | 100% | 99.9% | Hyperbiliverdinemia, 614156 |
| CARS1 | 100% | 99.9% | 100% | 100% | 99.2% | Microcephaly, developmental delay, and brittle hair syndrome, 618891 |
| CC2D2A | 98.2% | 98.2% | 100% | 100% | 99.6% | COACH syndrome 2, 619111; Retinitis pigmentosa 93, 619845; Meckel syndrome 6, 612284; Joubert syndrome 9, 612285 |
| CEP83 | 100% | 100% | 100% | 100% | 99.7% | Nephronophthisis 18, 615862 |
| CFC1 | 100% | 100% | 100% | 100% | 99.8% | Heterotaxy, visceral, 2, autosomal, 605376 |

| | | | | | | |
|--------|------|------|------|-------|-------|---|
| CFTR | 100% | 100% | 100% | 100% | 99.5% | Cystic fibrosis, 219700;Sweat chloride elevation without CF;Congenital bilateral absence of vas deferens, 277180;{Pancreatitis, hereditary}, 167800;{Bronchiectasis with or without elevated sweat chloride 1, modifier of}, 211400;{Hypertrypsine mia, neonatal} |
| CHD8 | 100% | 100% | 100% | 100% | 99.4% | Intellectual developmental disorder with autism and macrocephaly, 615032 |
| CHRM3 | 100% | 100% | 100% | 99.9% | 98.4% | Prune belly syndrome, 100100 |
| CHRNA3 | 100% | 100% | 100% | 99.9% | 99% | {Lung cancer susceptibility 2}, 612052;Bladder dysfunction, autonomic, with impaired pupillary reflex and secondary CAKUT, 191800 |
| CLDN1 | 100% | 100% | 100% | 100% | 99.5% | Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis, 607626 |
| CLMP | 100% | 100% | 100% | 100% | 99.4% | Congenital short bowel syndrome, 615237 |

| | | | | | | |
|---------|------|------|------|-------|-------|--|
| COG6 | 100% | 100% | 100% | 100% | 99.7% | Shaheen syndrome, 615328;Congenital disorder of glycosylation, type III, 614576 |
| COG7 | 100% | 100% | 100% | 100% | 99.2% | Congenital disorder of glycosylation, type IIe, 608779 |
| CYP27A1 | 100% | 100% | 100% | 99.9% | 99% | Cerebrotendinous xanthomatosis, 213700 |
| CYP7B1 | 100% | 100% | 100% | 100% | 99.7% | Spastic paraplegia 5A, autosomal recessive, 270800;Bile acid synthesis defect, congenital, 3, 613812 |
| DCDC2 | 100% | 100% | 100% | 100% | 99.4% | Nephronophthisis 19, 616217;?Deafness, autosomal recessive 66, 610212;Sclerosing cholangitis, neonatal, 617394 |

| | | | | | | |
|---------|-------|-------|------|-------|-------|--|
| DGUOK | 100% | 100% | 100% | 100% | 99.8% | Portal hypertension, noncirrhotic, 1, 617068; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 4, 617070; Mitochondrial DNA depletion syndrome 3 (hepatocerebral type), 251880 |
| DHCR7 | 96.2% | 96.1% | 100% | 100% | 99.4% | Smith-Lemli-Opitz syndrome, 270400 |
| DKC1 | 100% | 99.4% | 99% | 89.6% | 70.2% | ?Cataracts, hearing impairment, nephrotic syndrome, and enterocolitis 1, 301108; Dyskeratosis congenita, X-linked, 305000 |
| DNAJB11 | 100% | 100% | 100% | 100% | 99.4% | Polycystic kidney disease 6 with or without polycystic liver disease, 618061 |
| DNASE2 | 100% | 100% | 100% | 100% | 99% | Autoinflammatory-pancytopenia syndrome, 619858 |

| | | | | | | |
|-------|-------|-------|------|-------|-------|--|
| EDNRB | 100% | 100% | 100% | 100% | 99.4% | {Hirschsprung disease, susceptibility to, 2}, 600155;?ABCD syndrome, 600501;Waardenburg syndrome, type 4A, 277580 |
| EPHX1 | 100% | 100% | 100% | 99.9% | 98.7% | |
| ERBB3 | 100% | 100% | 100% | 100% | 98.8% | ?Lethal congenital contractural syndrome 2, 607598;(?Erythroleukemia, familial, susceptibility to), 133180;Visceral neuropathy, familial, 1, autosomal recessive, 243180 |
| ETFDH | 95.3% | 92.7% | 100% | 100% | 99.5% | Glutaric acidemia IIC, 231680 |
| FAH | 100% | 100% | 100% | 100% | 99.4% | Tyrosinemia, type I, 276700 |
| FARSB | 100% | 100% | 100% | 100% | 99.4% | Rajab interstitial lung disease with brain calcifications 1, 613658 |
| FECH | 100% | 100% | 100% | 100% | 99.8% | Protoporphyrin, erythropoietic, 1, 177000 |
| FH | 100% | 100% | 100% | 100% | 99.7% | Leiomyomatosis and renal cell cancer, 150800;Fumarate deficiency, 606812 |

| | | | | | | |
|-------|------|-------|-------|-------|-------|---|
| FLNA | 100% | 99.8% | 98.2% | 86.8% | 67.3% | Otopalatodigital syndrome, type II, 304120;Intestinal pseudoobstruction, neuronal, 300048;Cardiac valvular dysplasia, X-linked, 314400;?FG syndrome 2, 300321;Melnick-Needles syndrome, 309350;Terminal osseous dysplasia, 300244;Congenital short bowel syndrome, 300048;Otopalatodigital syndrome, type I, 311300;Heterotopia, periventricular, 1, 300049;Frontometaphyseal dysplasia 1, 305620 |
| FOCAD | 100% | 100% | 100% | 99.9% | 99.4% | Liver disease, severe congenital, 619991 |
| GALM | 100% | 100% | 100% | 100% | 99.3% | Galactosemia IV, 618881 |
| GALT | 100% | 100% | 100% | 100% | 99% | Galactosemia, 230400 |
| GANAB | 100% | 100% | 100% | 100% | 99.5% | Polycystic kidney disease 3, 600666 |

| | | | | | | |
|------|------|------|------|------|-------|--|
| GBA1 | 100% | 100% | 100% | 100% | 99.1% | {Lewy body dementia, susceptibility to}, 127750;Gaucher disease, type II, 230900;Gaucher disease, type IIIC, 231005;Gaucher disease, type III, 231000;Gaucher disease, type I, 230800;Gaucher disease, perinatal lethal, 608013;{Parkinson disease, late-onset, susceptibility to}, 168600 |
| GBE1 | 100% | 100% | 100% | 100% | 99.8% | Glycogen storage disease IV, 232500;Polyglucosan body disease, adult form, 263570 |
| GDNF | 100% | 100% | 100% | 100% | 99% | {Hirschsprung disease, susceptibility to, 3}, 613711 |
| GFM1 | 100% | 100% | 100% | 100% | 99.5% | Combined oxidative phosphorylation deficiency 1, 609060 |

| | | | | | | |
|--------|-------|-------|------|-------|-------|---|
| GLI3 | 99.3% | 99.3% | 100% | 99.9% | 99.1% | Greig cephalopolysyndactyly syndrome, 175700;Polydactyly, postaxial, types A1 and B, 174200;Pallister-Hall syndrome, 146510;Polydactyly, preaxial, type IV, 174700 |
| GLIS3 | 100% | 100% | 100% | 100% | 99.1% | Diabetes mellitus, neonatal, with congenital hypothyroidism, 610199 |
| HADHA | 100% | 100% | 100% | 100% | 99.5% | HELLP syndrome, maternal, of pregnancy, 609016;LCHAD deficiency, 609016;Mitochondrial trifunctional protein deficiency 1, 609015;Fatty liver, acute, of pregnancy, 609016 |
| HAMP | 100% | 100% | 100% | 100% | 99.2% | Hemochromatosis, type 2B, 613313 |
| HFE | 100% | 100% | 100% | 100% | 98.7% | Hemochromatosis, type 1, 235200 |
| HMGCS2 | 100% | 100% | 100% | 99.9% | 99.6% | HMG-CoA synthase-2 deficiency, 605911 |

| | | | | | | |
|---------|------|-------|-------|-------|-------|--|
| HNF1B | 100% | 100% | 100% | 100% | 99.4% | Type 2 diabetes mellitus, 125853;Renal cysts and diabetes syndrome, 137920;{Renal cell carcinoma}, 144700 |
| HSD17B4 | 100% | 100% | 100% | 100% | 99.6% | D-bifunctional protein deficiency, 261515;Perrault syndrome 1, 233400 |
| HSD3B7 | 100% | 100% | 100% | 100% | 99.6% | Bile acid synthesis defect, congenital, 1, 607765 |
| IARS1 | 100% | 100% | 100% | 100% | 99.6% | Growth retardation, impaired intellectual development, hypotonia, and hepatopathy, 617093 |
| IDS | 100% | 99.3% | 99.2% | 91.1% | 72.1% | Mucopolysaccharidosis II, 309900 |
| IFT140 | 100% | 100% | 100% | 100% | 99% | Short-rib thoracic dysplasia 9 with or without polydactyly, 266920;Retinitis pigmentosa 80, 617781 |
| IFT172 | 100% | 100% | 100% | 100% | 99.3% | Retinitis pigmentosa 71, 616394;Bardet-Biedl syndrome 20, 619471;Short-rib thoracic dysplasia 10 with or without polydactyly, 615630 |

| | | | | | | |
|-------|------|------|------|-------|-------|--|
| IFT43 | 100% | 100% | 100% | 100% | 99.4% | ?Cranioectodermal dysplasia 3, 614099;?Retinitis pigmentosa 81, 617871;Short-rib thoracic dysplasia 18 with polydactyly, 617866 |
| IFT56 | 100% | 100% | 100% | 100% | 99.7% | Biliary, renal, neurologic, and skeletal syndrome, 619534 |
| INSR | 100% | 100% | 100% | 99.9% | 98.9% | Rabson-Mendenhall syndrome, 262190;Diabetes mellitus, insulin-resistant, with acanthosis nigricans, 610549;Donohue syndrome, 246200;Hyperinsulinemic hypoglycemia, familial, 5, 609968 |
| INVS | 100% | 100% | 100% | 100% | 99.6% | Nephronophthisis 2, infantile, 602088 |
| JAG1 | 100% | 100% | 100% | 100% | 99.4% | ?Deafness, congenital heart defects, and posterior embryotoxon, 617992;Charcot-Marie-Tooth disease, axonal, type 2HH, 619574;Alagille syndrome 1, 118450;Tetralogy of Fallot, 187500 |

| | | | | | | |
|--------|------|-------|-------|-------|-------|---|
| KCNMA1 | 100% | 100% | 100% | 99.9% | 99% | {Epilepsy, idiopathic generalized, susceptibility to, 16}, 618596;Paroxysmal nonkinesigenic dyskinesia, 3, with or without generalized epilepsy, 609446;Cerebellar atrophy, developmental delay, and seizures, 617643;Liang-Wang syndrome, 618729 |
| KIF12 | 100% | 100% | 100% | 100% | 98.9% | Cholestasis, progressive familial intrahepatic, 8, 619662 |
| L1CAM | 100% | 99.7% | 98.4% | 87.6% | 68.6% | MASA syndrome, 303350;Hydrocephalus, congenital, X-linked, 307000;?Corpus callosum, partial agenesis of, 304100 |
| LARS1 | 100% | 100% | 100% | 99.9% | 99.3% | ?Infantile liver failure syndrome 1, 615438 |
| LARS2 | 100% | 100% | 100% | 100% | 99.6% | Perrault syndrome 4, 615300;Hydrops, lactic acidosis, and sideroblastic anemia, 617021 |
| LIG3 | 100% | 100% | 100% | 100% | 99.4% | Mitochondrial DNA depletion syndrome 20 (MNGIE type), 619780 |

| | | | | | | |
|--------|------|------|------|-------|-------|--|
| LMOD1 | 100% | 100% | 100% | 100% | 98.2% | ?Megacystis-microcolon-intestinal hypoperistalsis syndrome 3, 619362 |
| LRP5 | 100% | 100% | 100% | 99.9% | 98.3% | Osteopetrosis, autosomal dominant 1, 607634;[Bone mineral density variability 1], 601884;Polycystic liver disease 4 with or without kidney cysts, 617875;Endosteal hyperostosis, 144750;Osteoporosis-pseudoglioma syndrome, 259770;Exudative vitreoretinopathy 4, 601813 |
| LYN | 100% | 100% | 100% | 99.9% | 99.6% | Autoinflammatory disease, systemic, with vasculitis, 620376 |
| MAGEL2 | 100% | 100% | 100% | 100% | 99.4% | Schaaf-Yang syndrome, 615547 |
| MARS1 | 100% | 100% | 100% | 100% | 99.2% | Spastic paraplegia 70, autosomal recessive, 620323;Interstitial lung and liver disease, 615486;?Trichothiodystrophy 9, nonphotosensitive, 619692;Charcot-Marie-Tooth disease, axonal, type 2U, 616280 |

| | | | | | | |
|-------|------|-------|-------|-------|-------|--|
| MED12 | 100% | 99.6% | 98.6% | 87.4% | 67.4% | Lujan-Fryns syndrome, 309520;Ohdo syndrome, X-linked, 300895;Hardikar syndrome, 301068;Opitz-Kaveggia syndrome, 305450 |
| MPV17 | 100% | 100% | 100% | 100% | 99.6% | Charcot-Marie-Tooth disease, axonal, type 2EE, 618400;Mitochondrial DNA depletion syndrome 6 (hepatocerebral type), 256810 |
| MTM1 | 100% | 99.9% | 99.3% | 92.2% | 74.8% | Myopathy, centronuclear, X-linked, 310400 |
| MYH11 | 100% | 100% | 100% | 99.9% | 98.7% | Megacystis-microcolon-intestinal hypoperistalsis syndrome 2, 619351;Aortic aneurysm, familial thoracic 4, 132900;Visceral myopathy 2, 619350 |
| MYL9 | 100% | 100% | 100% | 99.9% | 99.1% | ?Megacystis-microcolon-intestinal hypoperistalsis syndrome 4, 619365 |

| | | | | | | |
|-------|-------|-------|------|-------|-------|---|
| MYLK | 99.2% | 99.2% | 100% | 99.9% | 99.2% | Megacystis-microcolon-intestinal hypoperistalsis syndrome 1, 249210;Aortic aneurysm, familial thoracic 7, 613780 |
| MYO5B | 100% | 100% | 100% | 100% | 99.4% | Diarrhea 2, with microvillus atrophy, with or without cholestasis, 251850;Cholestasis, progressive familial intrahepatic, 10, 619868 |
| NBAS | 100% | 99.9% | 100% | 100% | 99.7% | Short stature, optic nerve atrophy, and Pelger-Huet anomaly, 614800;Infantile liver failure syndrome 2, 616483 |
| NHP2 | 100% | 100% | 100% | 99.9% | 99% | Dyskeratosis congenita, autosomal recessive 2, 613987 |
| NOP10 | 92.5% | 92.5% | 100% | 100% | 98.8% | ?Pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 9, 620400;?Cataracts, hearing impairment, nephrotic syndrome, and enterocolitis 2, 620425;?Dyskeratosis congenita, autosomal recessive 1, 224230 |

| | | | | | | |
|--------|------|------|------|-------|-------|---|
| NOTCH2 | 100% | 100% | 100% | 100% | 99.7% | Alagille syndrome 2, 610205;Hajdu-Cheney syndrome, 102500 |
| NPC1 | 100% | 100% | 100% | 99.9% | 99.4% | Niemann-Pick disease, type C1, 257220;Niemann-Pick disease, type D, 257220 |
| NPC2 | 100% | 100% | 100% | 99.9% | 99.1% | Niemann-pick disease, type C2, 607625 |
| NPHP3 | 100% | 100% | 100% | 100% | 99.6% | Nephronophthisis 3, 604387;Renal-hepatic-pancreatic dysplasia 1, 208540;Meckel syndrome 7, 267010 |
| NR1H4 | 100% | 100% | 100% | 100% | 99.7% | Cholestasis, progressive familial intrahepatic, 5, 617049 |
| PEX1 | 100% | 100% | 100% | 100% | 99.8% | Heimler syndrome 1, 234580;Peroxisome biogenesis disorder 1B (NALD/IRD), 601539;Peroxisome biogenesis disorder 1A (Zellweger), 214100 |
| PEX10 | 100% | 100% | 100% | 100% | 99.6% | Peroxisome biogenesis disorder 6A (Zellweger), 614870;Peroxisome biogenesis disorder 6B, 614871 |

| | | | | | | |
|-------|------|------|------|-------|-------|---|
| PEX12 | 100% | 100% | 100% | 100% | 99.7% | Peroxisome biogenesis disorder 3B, 266510;Peroxisome biogenesis disorder 3A (Zellweger), 614859 |
| PEX13 | 100% | 100% | 100% | 100% | 99.7% | Peroxisome biogenesis disorder 11A (Zellweger), 614883;Peroxisome biogenesis disorder 11B, 614885 |
| PEX14 | 100% | 100% | 100% | 99.9% | 98.4% | Peroxisome biogenesis disorder 13A (Zellweger), 614887 |
| PEX16 | 100% | 100% | 100% | 99.9% | 99.1% | Peroxisome biogenesis disorder 8B, 614877;Peroxisome biogenesis disorder 8A (Zellweger), 614876 |
| PEX19 | 100% | 100% | 100% | 100% | 99.5% | Peroxisome biogenesis disorder 12A (Zellweger), 614886 |
| PEX2 | 100% | 100% | 100% | 100% | 99.7% | Peroxisome biogenesis disorder 5A (Zellweger), 614866;Peroxisome biogenesis disorder 5B, 614867 |
| PEX26 | 100% | 100% | 100% | 100% | 99.3% | Peroxisome biogenesis disorder 7B, 614873;Peroxisome biogenesis disorder 7A (Zellweger), 614872 |

| | | | | | | |
|-------|-------|-------|------|-------|-------|--|
| PEX3 | 100% | 100% | 100% | 100% | 99.8% | Peroxisome biogenesis disorder 10A (Zellweger), 614882;?Peroxisome biogenesis disorder 10B, 617370 |
| PEX5 | 100% | 100% | 100% | 99.7% | 98.5% | Peroxisome biogenesis disorder 2B, 202370;Peroxisome biogenesis disorder 2A (Zellweger), 214110;Rhizomelic chondrodysplasia punctata, type 5, 616716 |
| PEX6 | 100% | 100% | 100% | 99.8% | 98.5% | Peroxisome biogenesis disorder 4B, 614863;Peroxisome biogenesis disorder 4A (Zellweger), 614862;Heimler syndrome 2, 616617 |
| PEX7 | 97.9% | 97.9% | 100% | 100% | 99.6% | Rhizomelic chondrodysplasia punctata, type 1, 215100;Peroxisome biogenesis disorder 9B, 614879 |
| PHKG2 | 100% | 100% | 100% | 100% | 98.9% | Glycogen storage disease IXc, 613027 |
| PKD1 | 99.9% | 99.6% | 100% | 99.8% | 98.3% | Polycystic kidney disease 1, 173900 |

| | | | | | | |
|-------|------|------|------|-------|-------|---|
| PKD2 | 100% | 100% | 100% | 99.8% | 97.4% | Polycystic kidney disease 2, 613095 |
| PKHD1 | 100% | 100% | 100% | 99.9% | 99.5% | Polycystic kidney disease 4, with or without hepatic disease, 263200 |
| POLG | 100% | 100% | 100% | 100% | 99.5% | Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE), 607459;Mitochondrial DNA depletion syndrome 4B (MNGIE type), 613662;Mitochondrial DNA depletion syndrome 4A (Alpers type), 203700;Progressive external ophthalmoplegia, autosomal dominant 1, 157640;Progressive external ophthalmoplegia, autosomal recessive 1, 258450 |
| POMC | 100% | 100% | 100% | 100% | 99.5% | {Obesity, early-onset, susceptibility to}, 601665;Obesity, adrenal insufficiency, and red hair due to POMC deficiency, 609734 |

| | | | | | | |
|----------|------|------|------|-------|-------|--|
| PRKCSH | 100% | 100% | 100% | 100% | 99.2% | Polycystic liver disease 1, 174050 |
| RAD21 | 100% | 100% | 100% | 100% | 99.8% | Cornelia de Lange syndrome 4, 614701;?Mungan syndrome, 611376 |
| RFX6 | 100% | 100% | 100% | 99.9% | 99.5% | Mitchell-Riley syndrome, 615710 |
| RINT1 | 100% | 100% | 100% | 100% | 99.6% | Infantile liver failure syndrome 3, 618641 |
| RNU4ATAC | | | | | | Roifman syndrome, 616651;Lowry-Wood syndrome, 226960;Microcephalic osteodysplastic primordial dwarfism, type I, 210710 |
| RPGRIP1L | 100% | 100% | 100% | 100% | 99.7% | Joubert syndrome 7, 611560;Meckel syndrome 5, 611561;?COACH syndrome 3, 619113 |
| SC5D | 100% | 100% | 100% | 100% | 99.8% | Lathosterolosis, 607330 |
| SCO1 | 100% | 100% | 100% | 100% | 99.7% | Mitochondrial complex IV deficiency, nuclear type 4, 619048 |
| SCYL1 | 100% | 100% | 100% | 99.9% | 98.6% | Spinocerebellar ataxia, autosomal recessive 21, 616719 |
| SEC61B | 100% | 100% | 100% | 99.7% | 98% | |

| | | | | | | |
|----------|-------|-------|------|-------|-------|---|
| SEC63 | 100% | 100% | 100% | 100% | 99.6% | Polycystic liver disease 2, 617004 |
| SEMA7A | 100% | 100% | 100% | 99.9% | 98.8% | ?Cholestasis, progressive familial intrahepatic, 11, 619874;[Blood group, John-Milton-Hagen system], 614745 |
| SERPINA1 | 100% | 100% | 100% | 100% | 98.4% | Hemorrhagic diathesis due to antithrombin Pittsburgh, 613490;Emphysema due to AAT deficiency, 613490;Emphysema-cirrhosis, due to AAT deficiency, 613490 |
| SGO1 | 100% | 100% | 100% | 100% | 99.7% | Chronic atrial and intestinal dysrhythmia, 616201 |
| SKIC3 | 98.9% | 98.9% | 100% | 100% | 99.6% | Trichohepatoenteric syndrome 1, 222470 |
| SLC10A1 | 100% | 100% | 100% | 100% | 99.1% | Hypercholanemia, familial 2, 619256 |
| SLC25A13 | 100% | 100% | 100% | 100% | 99.7% | Citrullinemia, type II, neonatal-onset, 605814;Citrullinemia, adult-onset type II, 603471 |
| SLC40A1 | 100% | 100% | 100% | 100% | 99.7% | Hemochromatosis, type 4, 606069 |

| | | | | | | |
|--------|-------|-------|------|-------|-------|---|
| SLC51A | 100% | 100% | 100% | 99.9% | 98.4% | ?Cholestasis, progressive familial intrahepatic, 6, 619484 |
| SMPD1 | 100% | 100% | 100% | 99.9% | 99.1% | Niemann-Pick disease, type B, 607616;Niemann-Pick disease, type A, 257200 |
| SOX10 | 97.8% | 97.8% | 100% | 99.9% | 98.3% | Waardenburg syndrome, type 4C, 613266;PCWH syndrome, 609136;Waardenburg syndrome, type 2E, with or without neurologic involvement, 611584 |
| SPINT2 | 100% | 100% | 100% | 99.9% | 98.5% | Diarrhea 3, secretory sodium, congenital, syndromic, 270420 |
| STN1 | 87.1% | 87% | 100% | 100% | 99.6% | Cerebroretinal microangiopathy with calcifications and cysts 2, 617341 |
| TALDO1 | 100% | 100% | 100% | 99.9% | 97.6% | Transaldolase deficiency, 606003 |
| TBX19 | 100% | 100% | 100% | 99.9% | 99.2% | Adrenocorticotrophic hormone deficiency, 201400 |

| | | | | | | |
|------|------|------|------|-------|-------|---|
| TERC | | | | | | Pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 2, 614743;Dyskeratosis congenita, autosomal dominant 1, 127550 |
| TERT | 100% | 100% | 100% | 99.9% | 98.4% | Dyskeratosis congenita, autosomal dominant 2, 613989;Dyskeratosis congenita, autosomal recessive 4, 613989;Pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 1, 614742;{Melanoma, cutaneous malignant, 9}, 615134;{Leukemia, acute myeloid}, 601626 |
| TFR2 | 100% | 100% | 100% | 99.9% | 99% | Hemochromatosis, type 3, 604250 |
| TJP2 | 100% | 100% | 100% | 100% | 99.6% | Hypercholanemia, familial 1, 607748;Cholestasis, progressive familial intrahepatic 4, 615878 |

| | | | | | | |
|----------|-------|-------|------|-------|-------|---|
| TMEM67 | 96.1% | 96.1% | 100% | 100% | 99.8% | Nephronophthisis 11, 613550;{Bardet-Biedl syndrome 14, modifier of}, 615991;Joubert syndrome 6, 610688;Meckel syndrome 3, 607361;?RHYNS syndrome, 602152;COACH syndrome 1, 216360 |
| TMEM70 | 100% | 100% | 100% | 99.9% | 99.3% | Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2, 614052 |
| TOGARAM1 | 100% | 100% | 100% | 100% | 99.7% | Joubert syndrome 37, 619185 |
| TRAF3IP1 | 100% | 100% | 100% | 100% | 98.7% | Senior-Loken syndrome 9, 616629 |
| TRMU | 100% | 100% | 100% | 99.9% | 99.4% | {Deafness, mitochondrial, modifier of}, 580000;Liver failure, transient infantile, 613070 |
| TULP3 | 100% | 100% | 100% | 100% | 99.5% | Hepatorenocardiac degenerative fibrosis, 619902 |

| | | | | | | |
|--------|------|------|------|-------|-------|--|
| TWNK | 100% | 100% | 100% | 100% | 99.5% | Mitochondrial DNA depletion syndrome 7 (hepatocerebral type), 271245;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3, 609286;Perrault syndrome 5, 616138 |
| TYMP | 100% | 100% | 100% | 99.9% | 98.8% | Mitochondrial DNA depletion syndrome 1 (MNGIE type), 603041 |
| UBR1 | 98% | 98% | 100% | 100% | 99.6% | Johanson-Blizzard syndrome, 243800 |
| UGT1A1 | 100% | 100% | 100% | 100% | 99.3% | Crigler-Najjar syndrome, type I, 218800;[Bilirubin, serum level of, QTL1], 601816;Hyperbilirubinaemia, familial transient neonatal, 237900;Crigler-Najjar syndrome, type II, 606785;[Gilbert syndrome], 143500 |
| UNC13D | 100% | 100% | 100% | 100% | 99.2% | Hemophagocytic lymphohistiocytosis, familial, 3, 608898 |
| UNC45A | 100% | 100% | 100% | 100% | 99.3% | Osteohepatoenteric syndrome, 619377 |

| | | | | | | |
|---------|------|------|------|-------|-------|---|
| USP53 | 100% | 100% | 100% | 100% | 99.5% | Cholestasis, progressive familial intrahepatic, 7, with or without hearing loss, 619658 |
| VIPAS39 | 100% | 100% | 100% | 100% | 99.7% | Arthrogryposis, renal dysfunction, and cholestasis 2, 613404 |
| VPS33B | 100% | 100% | 100% | 99.9% | 99.4% | Keratoderma-ichthyosis-deafness syndrome, autosomal recessive, 620009;Cholestasis, progressive familial intrahepatic, 12, 620010;Arthrogryposis, renal dysfunction, and cholestasis 1, 208085 |
| VPS50 | 100% | 100% | 100% | 100% | 99.9% | Neurodevelopmental disorder with microcephaly, seizures, and neonatal cholestasis, 619685 |
| WDR35 | 100% | 100% | 100% | 100% | 99.6% | Short-rib thoracic dysplasia 7 with or without polydactyly, 614091;Cranioectodermal dysplasia 2, 613610 |

| | | | | | | |
|---------|------|------|------|------|-------|--|
| YARS1 | 100% | 100% | 100% | 100% | 99.5% | Infantile-onset multisystem neurologic, endocrine, and pancreatic disease 2, 619418;Charcot-Marie-Tooth disease, dominant intermediate C, 608323 |
| ZFYVE19 | 100% | 100% | 100% | 100% | 99.6% | Cholestasis, progressive familial intrahepatic, 9, 619849 |

Gene symbols used follow HGCN guidelines: Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Nucleic Acids Res. 2015 Jan 43(Database issue):D1079-85.

TWIST X2 covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x when analyzed by WES using TWIST X2 chemistry mapped against GRCh38.

TWIST X2 covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x when analyzed by WES using TWIST X2 chemistry mapped against GRCh38.

srWGS covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x when analyzed by WGS mapped against GRCh38.

srWGS covered 15x describes the percentage of a gene's coding sequence that is covered at least 15x when analyzed by WGS mapped against GRCh38.

srWGS covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x when analyzed by WGS mapped against GRCh38.

non-protein coding genes are covered, but as coverage statistics are based on protein coding regions, statistics could not be generated.

OMIM release used for OMIM disease identifiers and descriptions : November 25th, 2024.

This list is accurate for panel version DG 4.1.0

Ad 1. Blank field signifies a gene without a current OMIM association Ad 2. OMIM phenotype descriptions between {} signify risk factors